SOPH Key Statistics, Chart & Performance
The current stock price of SOPH is 4.67 USD. In the past month the price decreased by -7.52%. In the past year, price increased by 43.25%.
SOPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 28.84 | 36.69B | ||
| DOCS | DOXIMITY INC-CLASS A | 27 | 8.34B | ||
| WAY | WAYSTAR HOLDING CORP | 24.44 | 6.27B | ||
| HTFL | HEARTFLOW INC | N/A | 2.48B | ||
| CERT | CERTARA INC | 17.62 | 1.40B | ||
| SDGR | SCHRODINGER INC | N/A | 1.32B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.24B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 638.5 | 1.08B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.06B | ||
| PHR | PHREESIA INC | N/A | 1.01B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.74 | 919.86M | ||
| CTEV | CLARITEV CORP | N/A | 706.66M |
Related stock screener links
About SOPH
Company Profile
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. The company is headquartered in Rolle, Vaud and currently employs 423 full-time employees. The company went IPO on 2021-07-23. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The firm has offices in Switzerland, France, and the United States and operates worldwide.
Company Info
SOPHIA GENETICS SA
La Piece 12
Rolle VAUD CH
CEO: Jurgi Camblong
Employees: 423
Phone: 41216941060
SOPHIA GENETICS SA / SOPH FAQ
What does SOPH do?
SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. The company is headquartered in Rolle, Vaud and currently employs 423 full-time employees. The company went IPO on 2021-07-23. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The firm has offices in Switzerland, France, and the United States and operates worldwide.
Can you provide the latest stock price for SOPHIA GENETICS SA?
The current stock price of SOPH is 4.67 USD. The price decreased by -1.27% in the last trading session.
Does SOPHIA GENETICS SA pay dividends?
SOPH does not pay a dividend.
What is the ChartMill rating of SOPHIA GENETICS SA stock?
SOPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SOPH stock?
SOPH stock is listed on the Nasdaq exchange.
What is the analyst forecast for SOPH stock?
10 analysts have analysed SOPH and the average price target is 7.48 USD. This implies a price increase of 60.17% is expected in the next year compared to the current price of 4.67.
What is the next earnings date for SOPH stock?
SOPHIA GENETICS SA (SOPH) will report earnings on 2026-05-04.
SOPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SOPH. When comparing the yearly performance of all stocks, SOPH is one of the better performing stocks in the market, outperforming 88.27% of all stocks.
SOPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SOPH. SOPH may be in some trouble as it scores bad on both profitability and health.
SOPH Financial Highlights
Over the last trailing twelve months SOPH reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS decreased by -0.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.1% | ||
| ROE | -87.58% | ||
| Debt/Equity | 0.33 |
SOPH Forecast & Estimates
10 analysts have analysed SOPH and the average price target is 7.48 USD. This implies a price increase of 60.17% is expected in the next year compared to the current price of 4.67.
For the next year, analysts expect an EPS growth of -18.82% and a revenue growth 16.03% for SOPH